ADMA Biologics 15min chart shows Bollinger Bands narrowing, KDJ death cross.
PorAinvest
lunes, 22 de septiembre de 2025, 2:47 pm ET1 min de lectura
ADMA--
Over the past month, ADMA Biologics' stock has dropped by 5.18%, underperforming the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32% [1]. Analysts expect the company to post earnings of $0.16 per share in its upcoming release, representing year-over-year growth of 6.67% [1]. The consensus estimate for revenue is $130.1 million, up 8.56% from the prior-year quarter.
Technical indicators also suggest a potential downward trend. As of September 22, 2025, at 14:45, ADMA Biologics' 15-minute chart exhibited a narrowing of Bollinger Bands, accompanied by a KDJ Death Cross. This combination indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in stock price .
Valuation metrics show that ADMA Biologics is currently being traded at a Forward P/E ratio of 28.26, which is a premium compared to its industry average Forward P/E of 19.79 [1]. The Medical - Biomedical and Genetics industry, to which ADMA Biologics belongs, has a Zacks Industry Rank of 95, placing it in the top 39% of all 250+ industries [1].
Investors should keep an eye on ADMA Biologics' financial results and any changes in analyst estimates, as these can provide insights into the company's near-term business trends. The Zacks Rank system, which considers these estimate changes, has assigned ADMA Biologics a Zacks Rank of #3 (Hold) [1].
ADMA Biologics's 15-minute chart has exhibited a narrowing of Bollinger Bands, accompanied by a KDJ Death Cross as of September 22, 2025, at 14:45. This suggests a decrease in the magnitude of stock price fluctuations, coupled with a shift in momentum towards the downside, potentially leading to further decreases in stock price.
ADMA Biologics (ADMA) ended the recent trading session at $15.30, reflecting a -5.03% change from the preceding day's closing price. This move lagged behind the S&P 500's daily gain of 0.47%, while the Dow and tech-heavy Nasdaq added 0.11% and 0.94%, respectively [1].Over the past month, ADMA Biologics' stock has dropped by 5.18%, underperforming the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32% [1]. Analysts expect the company to post earnings of $0.16 per share in its upcoming release, representing year-over-year growth of 6.67% [1]. The consensus estimate for revenue is $130.1 million, up 8.56% from the prior-year quarter.
Technical indicators also suggest a potential downward trend. As of September 22, 2025, at 14:45, ADMA Biologics' 15-minute chart exhibited a narrowing of Bollinger Bands, accompanied by a KDJ Death Cross. This combination indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in stock price .
Valuation metrics show that ADMA Biologics is currently being traded at a Forward P/E ratio of 28.26, which is a premium compared to its industry average Forward P/E of 19.79 [1]. The Medical - Biomedical and Genetics industry, to which ADMA Biologics belongs, has a Zacks Industry Rank of 95, placing it in the top 39% of all 250+ industries [1].
Investors should keep an eye on ADMA Biologics' financial results and any changes in analyst estimates, as these can provide insights into the company's near-term business trends. The Zacks Rank system, which considers these estimate changes, has assigned ADMA Biologics a Zacks Rank of #3 (Hold) [1].
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios